Fulgent Genetics acquires Bako Diagnostics and StrataDx to offset precision diagnostics headwind
Fulgent Genetics closes $56.9M Bako and StrataDx acquisition. What it means for anatomic pathology growth, margin risk, and diagnostic consolidation in 2026.